Picture loading failed.

Pre-Made Fontolizumab biosimilar, Whole mAb, Anti-IFNG Antibody: Anti-IFG/IFI/IMD69 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease. A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-219-1mg 1mg 3090
GMP-Bios-ab-219-10mg 10mg Inquiry
GMP-Bios-ab-219-100mg 100mg Inquiry
GMP-Bios-ab-219-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Fontolizumab biosimilar, Whole mAb, Anti-IFNG Antibody: Anti-IFG/IFI/IMD69 therapeutic antibody
INN Name Fontolizumab
TargetIFNG
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI Structure1t3f:BA/1t04:DC:BA
95-98% SI StructureNone
Year Proposed2002
Year Recommended2003
CompaniesPDL BioPharma
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAutoimmune disorders;Crohn's disease;Psoriasis;Rheumatoid arthritis
Development Techna